All News

Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.

Executive previously served as chief financial officer of Moderna, Amgen, and 3M.

KYV-101 designed as a CD19 CAR T-cell therapy.

Sapio chemistry solution unifies small-molecule and large-molecule discovery workflows on a single platform.

GC1126A is designed to treat the rare blood disorder.

Kalinovich previously worked at Wabtec as a corporate vice president.

The gastric/gastroesophageal cancer treatment is produced by Transcenta.

Exec joins the organization with decades of biopharma experience.

The company announced that it is fully funded beyond clinical Phase IIb ALS results.

Copp comes to the company from McKinsey & Co.

EXXUA has been approved for treatment.

The company announced new hires for its chief scientific officer, chief business officer, and other leadership roles.

Hunt joins the company from HeartBeam.

Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.

The treatment is approved for conditional marketing authorization.

Via Nova Therapeutics’ VNT-101 is an Influenza A nucleoprotein inhibitor.

The device, Maverick, utilizes Raman spectroscopy for bioprocess control.

Location aims to translate research into multiple real-world treatments.

Barone is a former FDA officer.

The drug, 9MW3011, is also approved for clinical study by NMPA.

The blockbuster drug has previously been approved to treat multiple heart and diabetes-related conditions.

With treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.

The system will be part of a NPH study.

The drug now has a new approved dosing schedule.

The agency granted the treatment with 510(k) clearance.

ResVita will use the money to develop a treatment for severe atopic dermatitis.

Move comes amid company’s shift to focusing on healthcare innovation exclusively.

Submission to focus on maintenance therapy in adults with moderately to severely active Crohn’s disease.